secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001213900-23-078145
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics announces positive Phase 1b data for briquilimab in Fanconi Anemia; all 3 patients engrafted
--------------------------------------------------------------------------------

- All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recovery.
- Briquilimab was well tolerated without any complications; no briquilimab-related adverse events or toxicities.
- Study expansion to Phase 2a is ongoing, led by Stanford.
- Data to be presented at 2023 Fanconi Anemia Research Fund Scientific Symposium (Sept 28-Oct 1).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023078145/0001213900-23-078145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023078145/ea185533-8k_jasperthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-078145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer